Healthcare
Predictive Oncology Inc.(POAI)
Live Price
Offline$7.73
-5.39% today
Window Change
-63.52%
Window
Jun 23, 2025 โ May 18, 2026
- Market Cap
- $20.00M
- Revenue Growth
- -92.3%
- EPS Growth
- -496.9%
- Dividend Yield
- 0.0%
Coverage: 228 bars ยท Jun 23, 2025 โ May 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Predictive Oncology Inc. (POAI) is a Healthcare stock with a market cap of $20.00M and listed on NASDAQ. The stock last traded around $7.73 and down 63.5% across the available one-year price window (Jun 23, 2025 โ May 18, 2026). Baseline metrics include revenue growth of -92.3%, EPS growth of -496.9%, a dividend yield of 0.0%. What stands out right now is revenue -92.3%, EPS -496.9%, free cash flow +16.8% with operating margin -22688.6% and ROIC -57.6%. Valuation already assumes a fairly strong business story at price/sales 149.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines POAI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-92.3% vs +7.6% peer median
Operating Margin
Below sector median
-22688.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 8, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -92.3% and EPS is at -496.9%, with operating margin around -22688.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +51.9% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 8, 2026 | โ | +7.6% | -22.0% | +31.8% |
2026 Mar 31, 2026 | +13536.7% | +119.8% | +177.8% | +248.1% |
2025 Nov 14, 2025 | -234.8% | -6.2% | +0.0% | -16.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
POAI
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
POAI Max Drawdown
-92.17%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for POAI and SPY.
Company Overview
Predictive Oncology Inc.
NASDAQ Capital Market
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
- Leadership
- Raymond F. Vennare
- IPO Date
- May 3, 2010
- Employees
- 23
- Street Address
- 2915 Commers Drive
- Mailing
- Pittsburgh, MN, 55121
- Region
- Pittsburgh, MN, US
- Reporting Currency
- USD
- Investor Line
- 651 389 4800
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 149.5
- Price/Book
- 2.0
Growth
- Revenue
- -92.3%
- EPS
- -496.9%
- Free Cash Flow
- +16.8%
Profitability
- Gross Margin
- 42.0%
- Operating Margin
- -22688.6%
- Net Margin
- -186053.4%
- ROE
- 2959.0%
- ROIC
- -57.6%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 10.02
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.